Lecture 11: Ocular Drug Delivery II Flashcards

0
Q

What are aqueous eyedrops?

A

Account for >90% of marketed opthalmic formulations
Sterile and isotonic. They are buffered to pH of eye fluids (~7.2) usually with phosphate buffers. The accepted pH range is 6-8

Precorneal loss due to reflex tearing and nasolacrimal drainage resulting in limited resident time (1-2min)

There is low drug permeability through cornea

Pulse entry results in short duration of action

There is a low bioavailability (<10%)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
1
Q

What are conventional topical dosage forms?

A

Solutions
Suspensions
Ointments
Emulsions

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What are opthalmic suspensions?

A

Used for poorly water soluble drugs

Sterilisation step can cause physical instability

They provide a longer duration of effect than solutions as drug particles are retained in conjunctival cul de sac better than individual molecules

The drugs must be <10microns as bigger particles cause irritation

These eye drops must be shaken before use

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What are opthalmic ointments?

A

Viscous and slow flowing preparations

Consists of mineral oil, petrolatum, lanolin bases
Oleaginous bases can cause blurred vision

Used when a longer residence time for drug is required

Only to be used at night due to effects on vision

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What are opthalmic emulsions?

A

Emulsions can be used to accommodate lipophilic drugs in their oil phase (o/w emulsion)

O/W submicron emulsions could increase corneal penetration and ocular bioavailability

Main Limitation is the requirement of surfactant which may be toxic

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What are examples of novel ocular drug delivery systems?

A
Polymeric systems
In situ gelling systems
Colloidal delivery systems
Pro drugs
Cyclodextrins
Contact lenses
Ocular inserts
Inotophoresis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What are examples of polymeric systems?

A
Artifical tears used to treat dry eye
These use polymers like 
CMC- 
HPMC hydroxy... Methylcellulose 
PEG - polyethylene glycol
PVA -
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What are in situ gelling systems?

A

These turn into gel like structures in response to environmental stimuli such as mono or Divalent cations, or presence of lacrimal fluid.

Gellan gum, xanthan gum and carrageenan are used in in situ gels which respond to ionic strength

Carbopol is used in gels responsive to pH
POE is used in gels responsive to solvent exchange
Poloxamer is used in gels responsive to temperature

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What are examples of colloidal delivery systems?

A
Liposomes
Niosomes
Microemulsions
Nano emulsions
Polymeric NPs
CDs self assemblies
SLNs
NLCs
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What factors need to be considered when choosing a colloidal drug delivery system?

A

Solubility
Entrapment efficiency
Stability

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What are the advantages of using lipid based nanoparticles did topical ocular drug delivery?

A
  • both hydrophilic and lipophilic compounds can be entrapped
  • lipophilicity and cationic charge increases interaction with corneal epithelium leading to increased precorneal retention and bioavailability
  • ease of manufacturing so easy to modify currently available eye drops
  • long term stability
  • can control size of nanoparticles to achieve sustained release
  • low viscosity so easy to instil
  • physiological lipids used therefore no toxicity
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What are the potential for nano particulate eye drops?

A

Improved ocular bioavailability
Targets and site specific drug delivery
Reduced dose
Reduced systemic side effects

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What characterisation of ocular formulations need to be done?

A
Preformulation
Physicochemical properties
In vitro drug release
Ex vivo drug release
Toxicity
Animal studies
Clinical trials
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What is preformulation characterisation of ocular formulations?

A

Stage of drug development during which Physicochemical properties of the active pharmaceutical ingredients are characterised:

  • solubility in different media and solvents
  • dissolution of API
  • accelerated stability assessment under various conditions
  • solid state properties (polymorphs, particle size, particle shape etc.)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What is the problem with nanoparticles?

A

They have a low EE ~11%

While NLCs have an EE of 90%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

How is in vitro and ex vivo drug release carried out?

A

Using Franz diffusion cell which contains a donor chamber, a membrane and a receptor chamber

Drug is placed into the donor chamber

There is a sampling port connected to receptor chamber which allows you to take out fluid to test amount of drug in the receptor chamber

There is a stirrer bar to mix up the drug content in the medium

16
Q

How is toxicity tested?

A

Draize test: testing toxicity on animals

Now there are alternatives:

  • hens egg test using chorioallantoic membrane (HETCAM) to test conjunctival toxicity
  • bovine eye assay where all the different colloidal formulations are tested for corneal rented in and permeability
  • cell culture assays via use of MTT
  • histopathology toxicity
17
Q

What are the posterior segment diseases?

A

Degenerative (age related macular degeneration, retinitis pigmentosa)
Vascular (diabetic retinopathy, rental vein/artery occlusion, retinopathy of prematurity)
Inflammatory (uveitis- inflammation of retina and choroid)
Proliferative (proliferative vitreoretinopathy)
Infectious (endothalmitis, CMV retinitis)
Others (glaucoma, leading to optic neuropathy)

18
Q

What are the different ocular delivery routes for posterior segment diseases?

A

Periocular
Intracameral
Intravitreal

19
Q

What are the challenges of posterior ODD?

A

Diffusion through ocular vitreous (determined by age and disease)
Enzymatic degradation/elimination resulting in short half life
Permeation across retinal tissues

20
Q

What are the advantages of novel polymer implant for on-demand ocular drug delivery?

A
Site specific treatment
Lower doses required
Prolonged treatment options
Turntable drug release
Patient compliance increased
Easy termination of treatment